<DOC>
	<DOCNO>NCT03029208</DOCNO>
	<brief_summary>The study evaluate safety efficacy daprodustat compare rhEPO treatment anemia associate CKD subject start dialysis recently start dialysis . Previous trial dialysis subject anemia associate CKD demonstrate daprodustat could maintain hemoglobin 24 week minimal effect plasma erythropoietin ( EPO ) concentration . Daprodustat postulate associate few major adverse cardiovascular event raise hemoglobin without supraphysiologic EPO concentration associate intravenous ( IV ) rhEPO therapy , potentially avoid blood pressure ( BP ) elevation adverse effect high EPO level . This randomized , open-label ( sponsor blind ) study comprise three study period : screening period 2 week ( extend additional 4 week need ) , 52-week active treatment period , follow-up period 4 6 week . Approximately 300 subject 150 subject per treatment group randomize 1:1 receive daprodustat rhEPO ( darbepoetin alfa ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Daprodustat Compared Recombinant Human Erythropoietin ( rhEPO ) Subjects With Anemia Associated With Chronic Kidney Disease ( CKD ) Who Are Initiating Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>18 99 year age inclusive . Planning start chronic dialysis within next 4 week ( date screen visit ) OR start receive dialysis ( specify ) endstage renal disease maximum &lt; =90 day immediately prior randomization expect stop dialysis duration trial : Hemodialysis ( HD ) &gt; =2 time per week daily peritoneal dialysis ( PD ) ( Including continuous automate PD ) . Hemoglobin concentration measure HemoCue ( range inclusive ) : 8 10.5 g/dL ( 56.5 millimoles per liter [ mmol/L ] ) screen 811.0 g/dL ( 5 6.8 mmol/L ) randomization . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Note : The countryspecific requirement France follow informed consent process . The countryspecific requirement France eligibility inclusion study follow . Planned livingrelated donor kidney transplant study . Ferritin : &lt; =100 nanogram per milliliter ( ng/mL ) ( &lt; =100 microgram per liter [ mcg/L ] ) screen IV iron supplementation . Transferrin saturation ( TSAT ) : &lt; =20 % screen IV iron supplementation . Vitamin B12 ( cobalamin ) : Below low limit reference range screen vitamin B12 supplementation . Folate : &lt; 2.0 ng/mL ( &lt; 4.5 nanomoles per liter [ nmol/L ] ) screening . Aplasias : History bone marrow aplasia pure red cell aplasia ( PRCA ) . Other cause anemia : Pernicious anemia , thalassemia major , sickle cell disease , myelodysplastic syndrome . Gastrointestinal ( GI ) bleeding : Evidence actively bleed gastric , duodenal , esophageal ulcer disease clinically significant GI bleeding &lt; =10 week prior screen randomization ( Day 1 ) . Use Erythropoiesisstimulating agent ( ESA ) treatment within 8 week prior screen except limit use part dialysis initiation . Note : Limited use define 6 week short act ESA ( rhEPO biosimilars ; maximum 20000 unit total ) long act ESA ( darbepoetin alfa [ maximum 100 mcg total ] methoxy polyethylene glycolepoetin beta [ maximum 125 mcg total ] ) receive starting dialysis . Myocardial infarction acute coronary syndrome : &lt; =10 week prior screen randomization ( Day 1 ) . Stroke transient ischemic attack : &lt; =10 week prior screen randomization ( Day 1 ) . Chronic Class IV heart failure , define New York Heart Association ( NYHA ) functional classification system . Current uncontrolled hypertension determine Investigator would contraindicate use rhEPO . QT correction use Bazett 's ( QTcB ) ( Day 1 ) : QTcB &gt; 500 millisecond ( msec ) , QTcB &gt; 530 msec subject bundle branch block . There QTc exclusion subject predominantly pace rhythm . Liver disease ( one follow ) : 1 . Alanine transaminase ( ALT ) &gt; 2 time upper limit normal ( ULN ) ( screen ) . 2 . Bilirubin &gt; 1.5 time ULN ( screen ) ( NOTE : Isolated bilirubin &gt; 1.5 time ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 3 . Current unstable liver biliary disease per investigator assessment , generally define presence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , esophageal gastric varix , persistent jaundice , cirrhosis . NOTE : Stable chronic liver disease ( include asymptomatic gallstone , chronic hepatitis B C , Gilbert 's syndrome ) acceptable subject otherwise meet entry criterion . History malignancy within 2 year prior screen randomization ( Day 1 ) , currently receive treatment cancer , complex kidney cyst ( i.e . Bosniak Category II F , III IV ) &gt; 3 centimeter ( cm ) . The exception localize squamous cell basal cell carcinoma skin definitively treat &gt; =10 week prior screen . History severe allergic anaphylactic reaction hypersensitivity excipients investigational product darbepoetin alfa . Use strong Cytochrome P4502C8 ( CYP2C8 ) inhibitor ( example gemfibrozil ) strong CYP2C8 inducer ( example rifampin/rifampicin ) . Use investigational drug ( daprodustat see next criterion ) &lt; =30 day within five halflives investigational agent , whichever long prior screening . Any prior treatment daprodustat treatment duration &gt; 30 day . Females : Subject pregnant [ confirm positive serum human chorionic gonadotropin ( hCG ) test female reproductive potential ( FRP ) ] , subject breastfeeding , subject reproductive potential agree follow one contraceptive option List Highly Effective Methods Avoiding Pregnancy . Any condition , clinical laboratory abnormality , examination find investigator considers would put subject unacceptable risk , may affect study compliance ( example intolerance rhEPO ) prevent understand aim investigational procedure possible consequence study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Daprodustat , recombinant human erythropoietin , darbepoetin , anemia , chronic kidney disease , dialysis , ESRD</keyword>
</DOC>